Medistim Strengthens its Commercial Operations
Today, January 31st, Medistim announces the strengthening of its commercial operations with the appointment of Mr. Mike Karim as Chief Commercial Officer (CCO), reporting to the President and CEO.
Mr. Karim brings deep industry expertise, strategic insight, and a proven track record from leadership roles at esteemed companies such as Boston Scientific, Lombard Medical, Heart Ware, and Oxford Endovascular, with a focus on the cardiac and vascular fields. With a strong foundation in sales, he has led Sales, Marketing, and General Management functions, successfully driving growth in international markets.
Furthermore, leadership of Medistim’s AMERICAS sales region—including its largest current market and greatest growth opportunity, the USA—has been entrusted to Mr. Tony Winter. Mr. Winter brings extensive commercial leadership experience across the cardiac, vascular, interventional, and surgical sectors. With more than a decade at Medtronic, contributions to Synovis Life Technologies, and most recently, leadership of the U.S. sales organization at ACIST Medical Systems, he is well-positioned to drive Medistim’s continued expansion in the region.
“Medistim stands at a pivotal moment as we enter 2025, poised for significant growth driven by the launch of the INTUI software platform, which is advancing innovation in the Cardiac segment, and a focused strategy in the Vascular segment, supported by the PATENT study and our commitment to advancing Peripheral Bypass,” says Medistim President and CEO Kari E. Krogstad. “This is the perfect time to strengthen our commercial efforts. With these strategic additions to our team, enhanced commercial initiatives, and a focus on fostering collaboration and sharing best practices across all regions, I am confident we will accelerate growth throughout this year and beyond.”
In his CCO role, Mr. Karim will lead and support the efforts of Tony Winter (AMERICAS), Stephanie Stenhagen (EMEA), and Roger Morberg (APAC) as they continue driving Medistim’s growth and success.
